Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Sunshine Guojian Pharmaceutical Shanghai Co Ltd banner
S

Sunshine Guojian Pharmaceutical Shanghai Co Ltd
SSE:688336

Watchlist Manager
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
SSE:688336
Watchlist
Price: 58.8 CNY -0.78% Market Closed
Market Cap: ¥36.3B
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

Price Targets Summary
Sunshine Guojian Pharmaceutical Shanghai Co Ltd

Wall Street analysts forecast Sunshine Guojian Pharmaceutical Shanghai Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Sunshine Guojian Pharmaceutical Shanghai Co Ltd is 76.77 CNY with a low forecast of 73.69 CNY and a high forecast of 81.44 CNY.

Lowest Forecast
Wall Street Target
73.69 CNY
25% Upside
Average Forecast
Wall Street Target
76.77 CNY
31% Upside
Highest Forecast
Wall Street Target
81.44 CNY
39% Upside
Lowest
Price Target
73.69 CNY
25% Upside
Average
Price Target
76.77 CNY
31% Upside
Highest
Price Target
81.44 CNY
39% Upside
Sunshine Guojian Pharmaceutical Shanghai Co Ltd Competitors:
Price Targets
SSRM
SSR Mining Inc
-1% Downside
NNOX
Nano-X Imaging Ltd
244% Upside
LAND
Gladstone Land Corp
1% Upside
RCKT
Rocket Pharmaceuticals Inc
104% Upside
SSRM
SSR Mining Inc
-1% Downside
NNOX
Nano-X Imaging Ltd
244% Upside
LAND
Gladstone Land Corp
1% Upside
RCKT
Rocket Pharmaceuticals Inc
104% Upside
PTEN
Patterson-UTI Energy Inc
-9% Downside

Revenue
Forecast

1% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
1% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Revenue forecast
is not available for
Sunshine Guojian Pharmaceutical Shanghai Co Ltd

Operating Income
Forecast

-7% / Year
Past Growth
39% / Year
Estimated Growth
Estimates Accuracy
N/A
Average
-7% / Year
Past Growth
39% / Year
Estimated Growth
Estimates Accuracy
N/A
Average

For the last 6 years the compound annual growth rate for Sunshine Guojian Pharmaceutical Shanghai Co Ltd's operating income is -7%. The projected CAGR for the next 3 years is 39%.

What are analyst estimates?

Net Income
Forecast

11% / Year
Past Growth
-8% / Year
Estimated Growth
Estimates Accuracy
N/A
Average
11% / Year
Past Growth
-8% / Year
Estimated Growth
Estimates Accuracy
N/A
Average

For the last 6 years the compound annual growth rate for Sunshine Guojian Pharmaceutical Shanghai Co Ltd's net income is 11%. The projected CAGR for the next 3 years is -8%.

What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Sunshine Guojian Pharmaceutical Shanghai Co Ltd's stock price target?
Price Target
76.77 CNY

According to Wall Street analysts, the average 1-year price target for Sunshine Guojian Pharmaceutical Shanghai Co Ltd is 76.77 CNY with a low forecast of 73.69 CNY and a high forecast of 81.44 CNY.

What is Sunshine Guojian Pharmaceutical Shanghai Co Ltd's Operating Income forecast?
Projected CAGR
39%

For the last 6 years the compound annual growth rate for Sunshine Guojian Pharmaceutical Shanghai Co Ltd's operating income is -7%. The projected CAGR for the next 3 years is 39%.

What is Sunshine Guojian Pharmaceutical Shanghai Co Ltd's Net Income forecast?
Projected CAGR
-8%

For the last 6 years the compound annual growth rate for Sunshine Guojian Pharmaceutical Shanghai Co Ltd's net income is 11%. The projected CAGR for the next 3 years is -8%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 319,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.